menu
    • menu

    Company profile for Egis Pharmaceuticals PLC

    NEW Drugs in Dev: 1
    Egis Pharmaceuticals PLC-PSE
    News
    Capacity Expansion Investments are Ongoing in Körmend

    23 Mar 2026

    // PRESS RELEASE

    Egis receives the Top Employer 2026 recognition

    15 Jan 2026

    // PRESS RELEASE

    Dennis Gabor Award 2 laureates’ achievements are linked to Egis

    16 Dec 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Egis Pharmaceuticals

    Contact Supplier

    Website

    CPhI Milan

    Booth #7D74

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/excipient-market-overview-clariant-sets-up-its-first-peg-excipients-facility-in-us-india-harmonizes-22-excipient-monographs

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Related CompaniesRelated Companies

    About

    Egis is an EU-based, vertically integrated generic pharmaceutical company with over 110 years of experience across the entire value chain. Renowned for reliable supply, proprietary technologies, and a broad EU-GMP portfolio, Egis delivers high-quality medicines to over 100 countries. Its 500+ strong R&D team drives innovation across cardiovascular, CNS, and oncology segments, with a key focus on cardiometabolic therapies and fixed-dose combinations (FDCs). Egis also supports partners with robust API capabilities and dependable contract development and manufacturing services.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Egis Pharmaceuticals PLCHungary Flag
    Country
    Country
    Hungary
    Address
    Address
    1106 Budapest, Keresztúri út 30-38
    Telephone
    Telephone
    +36 18035555
    Client Email
    Email
    mailbox@egis.hu
    Client Website
    Website
    https://int.egis.health/home
    Linkedin
    Linkedin
    https://www.linkedin.com/company/egis-pharmaceuticals-plc/
    youtube
    YouTube
    http://www.youtube.com/@EgisPharma-rs6qr
    Twitter
    Twitter
    Contact Info
    Others

    FDFs
    fpd.opr@egis.hu
    APIs
    bulk.opr@egis.hu
    Services:
    pharmaservices@egis.hu

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Milan

    Booth #7D74

    envelop Contact Supplier

    CPhI Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-92718.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-9433.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Egis Leaflet

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-90894.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-22607.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-44964.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    APIs Under Development 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-47685.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pharma Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-party-content-3618.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-77278.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    CEP Q1 2026 Update: CEP 2.0, EDQM’s new guidelines strengthen ecosystem; Indian firms top list of CEPs issued

    PharmaCompass is introducing a new regulatory update that tracks developments in Certificates of Suitability to the Monographs of the European Pharmacopoeia, referred to as CEPs. These certificates are a critical regulatory instrument in the global pharmaceutical supply chain.Also known as a Certification of Suitability (COS), CEPs are issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), with or without inspection of the manufacturing site. A CEP must be renewed every five years from its original issue date to remain valid, regardless of any revisions made during the interim period. However, a CEP does not replace Good Manufacturing Practice certification.CEPs are recognized as a trusted reference for API quality, thereby simplifying global registration strategies. Apart from Europe, the CEP system is widely used by many regulatory authorities, including those in Canada, Australia, Brazil, Singapore and South Africa. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)CEP 2.0 enhances regulatory clarity, brings efficiency, global interoperability There are several types of CEPs, depending on the nature of the substance and evaluation. The most common type is the Chemical CEP, which confirms that a chemically synthesized API meets standards for purity and impurity control. Then there are Herbal CEPs for herbal substances and preparations.Another key category is the TSE CEP, which addresses risks associated with transmissible spongiform encephalopathies in animal-derived materials. In addition, there are Combined CEPs that may cover multiple aspects, such as chemical quality, TSE risk, and sterility. However, biological products such as vaccines and blood products fall outside the scope of the CEP framework.In 2023, the CEP system underwent a major transformation with the introduction of CEP 2.0, which marks a shift from a largely document-based system to a more structured, transparent, and digitally aligned model. This makes it easier for companies to manage compliance while improving trust among global regulators.While increasing data and compliance requirements for API manufacturers, CEP 2.0 enables better regulatory clarity, streamlined dossier integration, and stronger global acceptance. Overall, CEP 2.0 is designed to enhance regulatory clarity while making the system more efficient and globally interoperable. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Indian firms issued maximum CEPs; Sun Pharma and its subsidiaries, Jubilant Biosys top listIndia topped the charts for CEPs issued, both in terms of new CEPs and revisions in the first quarter (Q1) of 2026. Indian companies were issued 81 new CEPs in Q1 2026 (as against 40 in Q1 2025) and 203 revisions (as against 129 in Q1 2025). In comparison, Chinese companies were issued 42 new CEPs in Q1 2026 (against 25 in Q1 2025) and 53 revisions (against 67 in Q1 2025). Italy came a distant third, followed by Germany and Spain.India’s Sun Pharmaceuticals and its subsidiaries topped the list of companies with the maximum number of CEPs issued— while no new CEP was issued, 27 CEPs were revised in Q1 2026. At second place was Jubilant Biosys — 21 CEPs were revised in Q1 2026.In terms of products, the maximum CEPs were issued for amlodipine besylate (a calcium channel blocker used for treating hypertension), followed by sitagliptin phosphate (a type 2 diabetes medicine) and pregabalin (a drug used to treat neuropathic pain, fibromyalgia, seizures, and generalized anxiety disorder). Both amlodipine besylate and sitagliptin phosphate had not been issued new CEPs or revisions in Q1 2025. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)EDQM introduces new guidelines to accelerate CEP assessments The EDQM charges fees for various services related to CEPs that depend on the type of request or regulatory activity involved. In general, fees apply to handling CEP applications, revisions or renewals and for offering technical advice (where applicants seek scientific or regulatory guidance).In March 2026, the EDQM introduced two new guidelines aimed at accelerating CEP assessments. The first is a reliance-based assessment pathway, which allows regulators to leverage prior approvals from trusted authorities, such as those in the EU, UK, Australia, Canada, and the WHO pre-qualification program. The second is a fast-track assessment route designed to expedite reviews in situations such as medicine shortages and to support initiatives like the EU Critical Medicines Act.Timelines have been significantly compressed under these new pathways. Initial evaluations are completed within 46 working days, compared to up to 115 days under the standard procedure. Applicants are given 30 calendar days to respond to queries, after which regulators complete the final assessment within 23 working days.Another important regulatory update relates to electronic submissions. From April 1, 2026, the EDQM will reject non-compliant CEP applications at the point of submission. All applications must include a validated electronic Common Technical Document (eCTD) dossier along with a proper validation report, submitted in line with the updated Common European Submission Portal (CESP) guidelines. Taken together, these developments signal a more rigorous yet efficient CEP ecosystem. View CEPs Issued in Q1 2026 (Power BI Dashboard, Free Excel Available)Our viewThe shift to CEP 2.0 signals a move toward greater transparency, digitalization, and global regulatory alignment. Though enhanced disclosure and stricter e-submission requirements may increase the compliance burden, especially for smaller manufacturers, the long-term gains are expected to be significant. Going forward, companies that invest in data quality and regulatory readiness stand to gain from these changes.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1483

    https://www.pharmacompass.com/radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    #PharmaFlow by PHARMACOMPASS
    09 Apr 2026
    Share Share
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3969

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 9626

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share
    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    US drug shortages reduce 16% YoY in Q1 2025; CNS drugs, antimicrobials face highest scarcities

    The pharmaceutical industry in the United States continued to grapple with drug shortages during the first quarter (Q1) of 2025. According to the American Society of Health‑System Pharmacists (ASHP), the total number of active shortages stood at 270 as of March 31, 2025 — only slightly below the 277 reported in September 2024, but down 16.4 percent from an all‑time high of 323 reported in Q1 2024.These numbers imply that while dramatic surges in drug shortages may have subsided, underlying vulnerabilities in manufacturing, supply chains, and raw‑material sourcing continue to frustrate efforts towards a durable resolution.A deeper analysis of these drug scarcities reveals that 41 percent of the 270 active shortages first emerged in 2022 or earlier. This implies that many of the current disruptions have become chronic in nature and are exerting pressure on pharmacy operations. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available)CNS drugs dominate with 49 meds in short supply; antimicrobials face shortage of 39 drugsClass‑specific analysis reveals that central nervous system (CNS) agents remained the most disrupted category, with 49 distinct CNS drugs having faced scarcities during Q1. This group spans anxiolytics (anti-anxiety drugs) such as clonazepam and flurazepam, sedatives like lorazepam and midazolam, and stimulants such as methylphenidate and lisdexamfetamine. These shortages pose two challenges — controlling seizures and managing sedation in acute care settings. After CNS agents, antimicrobials was the second‑largest category, with shortages affecting 39 drugs. Key antibacterial and anti-fungal agents such as cefotaxime sodium powder for injection, clindamycin phosphate, rifampin, and metronidazole find themselves on ASHP’s active‑shortage roster, threatening both routine hospital protocols and emergency sepsis management.Fluids and electrolytes occupied the third spot, with 29 items facing shortage in Q1 2025. Hormone agents, including insulin analogs, ranked fourth with 24 drugs in short supply.Chemotherapy medications rounded out the top five categories, with 23 antineoplastic agents (a broad class of medications used to treat cancer) flagged as actively constrained in Q1 2025. Notable shortages included azacitidine, carboplatin, methotrexate, and streptozocin. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) US faces 26 new shortages; Pharmacopeia list warns of 100 vulnerable medicationsThe first quarter saw the emergence of 26 new shortage declarations, emphasizing that even drugs previously deemed reliably sourced can fall into scarcity. The US has been facing a shortage of attention deficit hyperactivity disorder (ADHD) drugs since 2022. The new shortages included ADHD transdermal patch methylphenidate, peginterferon alfa‑2a (Pegasys) used in chronic hepatitis B and C, and bacitracin ophthalmic ointment.The fragility of the pharmaceutical supply chains has been particularly evident in the aftermath of natural disasters. Hurricane Helene’s flooding at Baxter’s Marion, North Carolina, facility deeply affected IV‑solution supply lines. Baxter supplies roughly 60 percent of the US’ IV fluids and the ASHP report listed “hurricane” as the reason behind nine percent of drug shortages, as of January 2025.Regulatory and policy interventions continue to evolve. The US Pharmacopeia’s inaugural Vulnerable Medicines List, launched in 2025, identifies 100 drugs at the highest risk of future shortages, with a particular focus on injectables (comprising 71 percent of the list) and essential hospital care.Antibiotics, medications for pain management and oncology are the other drugs on the list. Although 61 percent of these vulnerable medicines were not in active shortage at the time of listing, their inclusion is intended to galvanize manufacturers and purchasing organizations to bolster inventories.Meanwhile, the Government Accountability Office in the US has called on the Department of Health and Human Services (HHS) to establish a formal coordination mechanism, warning that elimination of the HHS supply‑chain coordinator role in May 2025 risks fragmenting federal response efforts. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Global shortages mirror US patterns; Europe launches monitoring platform Globally, we notice comparable trends. For instance, Europe has rolled out the European Shortages Monitoring Platform (ESMP) this year in order to centralize shortage reporting across member states. Critical‑medicine shortages in the EU — in areas such as oncology, ADHD, and critical care analgesics — mirror US patterns. The European Medicines Agency’s shortage list currently holds 37 human drugs.According to Health Canada’s May 12, 2025 update, its Tier 3 list had 18 drug shortages that are considered to have the greatest impact on Canada’s drug supply and health‑care system. Tier 3 designation is based on medical necessity and minimal availability of alternatives.In hematology and oncology, scarcity of essential drugs like Oncaspar for acute lymphoblastic leukemia, idarubicin and lomustine for leukemias and brain tumors, anagrelide for thrombocythemia, and preservative‑free methotrexate for various malignancies underscore the impact these drug shortages can have on treatment. View Our Interactive Dashboard on Drug Shortages So Far in 2025 (Free Excel Available) Our viewThe global pharma supply chain is dealing with a fresh wave of uncertainties, especially with the likelihood of tariffs on drugs imported into the US. Analysts warn that the proposed pharmaceutical tariffs could exacerbate supply issues.Over 50 percent of drugs used in the US are manufactured abroad. Generic sterile injectable drugs — like chemotherapy medications and IV saline — are particularly vulnerable due to their complex manufacturing processes and low profit margins. Generic drugs (which account for 90 percent of prescriptions filled in the US) could face increased pressure, as many rely on raw materials from China and India. This could result in more severe drug shortages in the future. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 5053

    https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities

    #PharmaFlow by PHARMACOMPASS
    22 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Capacity Expansion Investments are Ongoing in Körmend
    Capacity Expansion Investments are Ongoing in Körmend

    23 Mar 2026

    // PRESS RELEASE

    https://int.egis.health/a/capacity-expansion-investments-are-ongoing-in-kormend

    PRESS RELEASE
    23 Mar 2026
    Share Share
    Egis receives the Top Employer 2026 recognition
    Egis receives the Top Employer 2026 recognition

    15 Jan 2026

    // PRESS RELEASE

    https://int.egis.health/a/dennis-gabor-award-two-laureates-achievements-are-linked-to-egis

    PRESS RELEASE
    15 Jan 2026
    Share Share
    Dennis Gabor Award 2 laureates’ achievements are linked to Egis
    Dennis Gabor Award 2 laureates’ achievements are linked to Egis

    16 Dec 2025

    // PRESS RELEASE

    https://int.egis.health/a/dennis-gabor-award-two-laureates-achievements-are-linked-to-egis

    PRESS RELEASE
    16 Dec 2025
    Share Share
    Egis Pharma Inaugurates New Active Ingredient Manufacturing Plant
    Egis Pharma Inaugurates New Active Ingredient Manufacturing Plant

    20 Nov 2025

    // PRESS RELEASE

    https://int.egis.health/a/egis-pharmaceuticals-plc-inaugurates-new-active-ingredient-manufacturing-plant

    PRESS RELEASE
    20 Nov 2025
    Share Share
    Egis Pharma And BME Partner To Advance Engineering Innovation
    Egis Pharma And BME Partner To Advance Engineering Innovation

    01 Sep 2025

    // PRESS RELEASE

    https://int.egis.health/a/egis-pharmaceuticals-plc-and-the-faculty-of-mechanical-engineering-at-bme-sign-cooperation-agreement

    PRESS RELEASE
    01 Sep 2025
    Share Share
    Egis Invests Over HUF 14 Billion in Körmend Site Development
    Egis Invests Over HUF 14 Billion in Körmend Site Development

    28 Jul 2025

    // PRESS RELEASE

    https://int.egis.health/a/egis-invests-over-huf-14-billion-in-kormend-site-development

    PRESS RELEASE
    28 Jul 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

    Details:

    The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the application of Pliaglis.


    Lead Product(s): Lidocaine,Tetracaine

    Therapeutic Area: Neurology Brand Name: Pliaglis

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Crescita Therapeutics

    Deal Size: Undisclosed Upfront Cash: $0.7 million

    Deal Type: Licensing Agreement December 13, 2021

    Egis Pharmaceuticals

    01

    Egis Pharmaceuticals PLC

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Lead Product(s) : Lidocaine,Tetracaine

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Crescita Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

    Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...

    Product Name : Pliaglis

    Product Type : Miscellaneous

    Upfront Cash : $0.7 million

    December 13, 2021

    Egis Pharmaceuticals

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Egis Favipiravir Drug Licenced for Covid-19 Treatment

    Details:

    The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).


    Lead Product(s): Favipiravir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Favipiravir-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: National Institute of Pharmacy and Nutrition

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 20, 2020

    Egis Pharmaceuticals

    02

    Egis Pharmaceuticals PLC

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Lead Product(s) : Favipiravir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : National Institute of Pharmacy and Nutrition

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Egis Favipiravir Drug Licenced for Covid-19 Treatment

    Details : The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).

    Product Name : Favipiravir-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    December 20, 2020

    Egis Pharmaceuticals

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : Abemaciclib

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Abemaciclib

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Abemaciclib

    Dosage Strength : 50MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Abemaciclib

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Abemaciclib

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Abemaciclib

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Abemaciclib

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Abemaciclib

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Abemaciclib

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Abemaciclib

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Abemaciclib

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Abemaciclib

    Dosage Strength : 200MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Viacoram

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info : Authorized

    Registration Country : Spain

    Amlodipine Besylate; Perindopril Arginine

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Viacoram

    Dosage Strength : 3.5MG;2.5MG

    Packaging :

    Approval Date : 09-09-2025

    Application Number : OGYIT2057205IP1

    Regulatory Info : Authorized

    Registration Country : Spain

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Viacoram

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info : Authorized

    Registration Country : Spain

    Amlodipine Besylate; Perindopril Arginine

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Viacoram

    Dosage Strength : 7MG;5MG

    Packaging :

    Approval Date : 09-09-2025

    Application Number : OGYIT2057206

    Regulatory Info : Authorized

    Registration Country : Spain

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Viacoram

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info : Authorized

    Registration Country : Spain

    Amlodipine Besylate; Perindopril Arginine

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Viacoram

    Dosage Strength : 3.5MG;2.5MG

    Packaging :

    Approval Date : 12-11-2024

    Application Number : OGYIT2057205IP

    Regulatory Info : Authorized

    Registration Country : Spain

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Aripiprazole

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Aripiprazole

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Aripiprazole

    Dosage Strength : 5MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Aripiprazole

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Aripiprazole

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Aripiprazole

    Dosage Strength : 10MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Aripiprazole

    Hungary
    arrow
    CPhI Milan
    Booth #7D74
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Regulatory Info :

    Registration Country : Hungary

    Aripiprazole

    Egis Pharmaceuticals PLC

    Dosage Form : Tablet

    Brand Name : Aripiprazole

    Dosage Strength : 15MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Hungary

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Egis Pharmaceuticals full-view
    Development of Chemical Intermediates
    full-view
    Small Molecule API Development Services
    full-view
    Intermediates for Anti-Cancer APIs
    full-view
    Highly Potent API (HPAPI) Manufacturing
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Egis Pharmaceuticals and get a quotation

    Egis Pharmaceuticals is a supplier offers 47 products (APIs, Excipients or Intermediates).

    Find Promethazine Hydrochloride bulk with DMF, CEP, JDMF offered by Egis Pharmaceuticals

    Find Allopurinol bulk with CEP, JDMF offered by Egis Pharmaceuticals

    Find Chlorpromazine Hydrochloride bulk with CEP, JDMF offered by Egis Pharmaceuticals

    Find Ethacrynic Acid bulk with DMF, CEP offered by Egis Pharmaceuticals

    Find Allopurinol bulk with CEP offered by Egis Pharmaceuticals

    Find Amlodipine Besylate bulk with CEP offered by Egis Pharmaceuticals

    Find Carvedilol bulk with CEP offered by Egis Pharmaceuticals

    Find Duloxetine Hydrochloride bulk with CEP offered by Egis Pharmaceuticals

    Find Levomepromazine Maleate bulk with CEP offered by Egis Pharmaceuticals

    Find Methyldopa bulk with CEP offered by Egis Pharmaceuticals

    Find Quetiapine Hemifumarate bulk with CEP offered by Egis Pharmaceuticals

    Find Tofisopam bulk with JDMF offered by Egis Pharmaceuticals

    Find ABEMACICLIB USP bulk with DMF offered by Egis Pharmaceuticals

    Find Abrocitinib bulk offered by Egis Pharmaceuticals

    Find Acalabrutinib bulk offered by Egis Pharmaceuticals

    Find Avapritinib bulk offered by Egis Pharmaceuticals

    Find Bisoprolol Fumarate bulk offered by Egis Pharmaceuticals

    Find Blarcamesine bulk offered by Egis Pharmaceuticals

    Find Capivasertib bulk offered by Egis Pharmaceuticals

    Find Clomiphene Citrate bulk offered by Egis Pharmaceuticals

    Find Crotamiton bulk offered by Egis Pharmaceuticals

    Find Dabrafenib Mesylate bulk offered by Egis Pharmaceuticals

    Find Dapagliflozin Propanediol Monohydrate bulk offered by Egis Pharmaceuticals

    Find Darolutamide bulk offered by Egis Pharmaceuticals

    Find Deucravacitinib bulk offered by Egis Pharmaceuticals

    Find Donepezil bulk offered by Egis Pharmaceuticals

    Find Empagliflozin bulk offered by Egis Pharmaceuticals

    Find Etrasimod bulk offered by Egis Pharmaceuticals

    Find Fezolinetant bulk offered by Egis Pharmaceuticals

    Find Ketoprofen bulk offered by Egis Pharmaceuticals

    Find LCZ 696 bulk offered by Egis Pharmaceuticals

    Find Levocetirizine Dihydrochloride bulk offered by Egis Pharmaceuticals

    Find Mavacamten bulk offered by Egis Pharmaceuticals

    Find Nifedipine bulk offered by Egis Pharmaceuticals

    Find Niraparib Tosylate bulk offered by Egis Pharmaceuticals

    Find Nitrendipine bulk offered by Egis Pharmaceuticals

    Find Osimertinib Mesylate bulk offered by Egis Pharmaceuticals

    Find Ozanimod bulk offered by Egis Pharmaceuticals

    Find Ramipril bulk offered by Egis Pharmaceuticals

    Find Repotrectinib bulk offered by Egis Pharmaceuticals

    Find Resmetirom bulk offered by Egis Pharmaceuticals

    Find Ribociclib bulk offered by Egis Pharmaceuticals

    Find Rivaroxaban bulk offered by Egis Pharmaceuticals

    Find Tofisopam bulk offered by Egis Pharmaceuticals

    Find Troriluzole bulk offered by Egis Pharmaceuticals

    Find Upadacitinib bulk offered by Egis Pharmaceuticals

    Find Zanubrutinib bulk offered by Egis Pharmaceuticals

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search